Cirrhosis and intestinal B-cell lymphoma: two entities that are rarely associated with celiac disease.
Ali Erkan
AE
Duman
Deniz
D
Oğütmen Koç
Uğur
U
Korkmaz
Ayşegül
A
Tohumcu
Altay
A
Celebi
Omer
O
Sentürk
Saadettin
S
Hülagü
Cengiz
C
Erçin
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002446:Celiac Disease / Q000150:complications*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004378:Duodenal Diseases / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone